Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Planned pivotal phase III trial of gimatecan vs topotecan in refractory patients with advanced epithelial ovarian, fallopian or peritoneal cancer, resistant or partially sensitive to platinum in China

Next Previous
X
Search
Trial Profile

Planned pivotal phase III trial of gimatecan vs topotecan in refractory patients with advanced epithelial ovarian, fallopian or peritoneal cancer, resistant or partially sensitive to platinum in China

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 07 Aug 2013

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gimatecan (Primary) ; Topotecan
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Lee's Pharmaceutical

    • Most Recent Events

    • 07 Aug 2013 A clinical trial application for this trial, given fast-track designation, has been accepted for review by the China FDA, according to a media release from Lees Pharmaceutical Holdings. The company hopes to initiate this trial in the second half of 2014.
    • 07 Aug 2013 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top